BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Rhea-AI Summary

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported preliminary Phase 1 safety and antitumor data across three oral RAS/PI3Kα programs: BBO-8520, BBO-11818, and BBO-10203. Key highlights include a 65% ORR (11/17) and 66% 6-month PFS in KRASG12C NSCLC with BBO-8520 monotherapy (data cutoff Nov 15, 2025), durable responses in combination with pembrolizumab, and responses in KRASG12C/STK11 and/or KEAP1 co-mutants. BBO-11818 showed a confirmed PR in pretreated PDAC with a 56% tumor reduction at higher dose levels (data cutoff Dec 10, 2025). BBO-10203 selected a 500 mg QD expansion dose, reported no hyperglycemia, and is advancing combination cohorts. Additional combination and expansion data expected H2 2026.

Positive

• BBO-8520 ORR of 65% (11/17) in KRASG12C NSCLC
• 66% 6-month PFS for BBO-8520-treated NSCLC patients
• All five initial KRASG12C/STK11 and/or KEAP1 co-mutant patients achieved PR
• BBO-11818 confirmed PR with 56% tumor reduction in PDAC
• BBO-10203 selected 500 mg QD recommended expansion dose
• BBO-10203 showed no hyperglycemia across enrollment without HbA1c restrictions

Negative

• Efficacy cohorts remain small (e.g., 17 efficacy-evaluable patients for BBO-8520)
• BBO-11818 response was initially unconfirmed at data cutoff
• One grade ≥3 lab abnormality (asymptomatic hypokalemia) with BBO-10203

Key Figures

ORR in KRASG12C NSCLC 65% BBO-8520 monotherapy across all dose levels as of Nov 15, 2025

6-month PFS 66% BBO-8520 monotherapy in KRASG12C NSCLC as of Nov 15, 2025

Patients on ≥6 months 83% KRASG12C NSCLC patients eligible for 6-month follow-up on BBO-8520

Responses / patients 11/17 Objective responses among NSCLC patients with KRASG12C on BBO-8520

PDAC tumor reduction 56% Tumor shrinkage in a PDAC patient on BBO-11818 monotherapy

BBO-10203 dose 500 mg QD Recommended expansion dose based on safety, PK and target engagement

BBO-11818 exposure 600 mg BID Dose reported to cover G12D and G12V mutant alleles

BBO-11818 patients 13 Number of patients treated with BBO-11818 monotherapy in dose escalation

Market Reality Check

$12.10 Last Close

Volume Volume 174,249 is roughly in line with the 20-day average 190,066 (relative volume 0.92). normal

Technical Price $11.59 is trading slightly above the 200-day MA at $11.50 and about 22% below the 52-week high.

Peers on Argus

BBOT was up 2.2% while close peers showed mixed moves (e.g., AVXL -2.79%, PRAX +0.59%, IMNM +0.51%), suggesting a stock-specific reaction rather than a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Conference presentation	Positive	-1.3%	Announcement of J.P. Morgan healthcare conference presentation and webcast access.
Dec 11	Equity compensation	Negative	-1.9%	Inducement stock option grant under 2025 Inducement Plan for a new hire.
Dec 10	Preclinical data	Positive	+2.8%	Late-breaking preclinical BBO-10203 RAS:PI3Kα breaker data at SABCS showing anti-tumor activity.
Nov 18	Investor conferences	Neutral	-1.8%	Participation in upcoming December investor healthcare conferences with webcast access.
Nov 12	Earnings & update	Neutral	-0.9%	Q3 2025 results with $468.3M liquidity, SPAC completion, and pipeline progress update.

Pattern Detected

Recent newsflow has produced relatively modest single‑digit moves, with a mix of alignment and divergence between event tone and price reaction.

Recent Company History

Over the last few months, BBOT transitioned to public markets, strengthened liquidity to $468.3M, and highlighted three Phase 1 RAS/PI3Kα programs with initial data expected in 2026. Preclinical BBO‑10203 data on Dec 10, 2025 drove a positive 2.79% move, while conference and corporate updates often saw small declines. Today’s clinical update advances the same pipeline, now with early human efficacy and safety signals across BBO‑8520, BBO‑11818, and BBO‑10203.

Market Pulse Summary

This announcement details encouraging Phase 1 data across BBOT’s three RAS and PI3Kα programs, including a 65% ORR and 66% 6‑month PFS for BBO‑8520 in KRASG12C NSCLC and a confirmed PR with 56% tumor reduction in PDAC on BBO‑11818. BBO‑10203 showed differentiated safety without hyperglycemia and a go‑forward 500 mg dose. Investors may watch upcoming 2026 combination data, durability of responses, and expansion‑cohort results.

Key Terms

krasg12c medical

"BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65%"

KRAS G12C is a specific genetic change in the KRAS gene where one building block of the gene is swapped, causing a protein to stay stuck in an “on” position that drives some cancers to grow. It matters to investors because medicines that specifically block this faulty protein can change treatment choices, patient outcomes, and revenue prospects for drug developers—similar to fixing a stuck switch that controls a machine’s behavior.

nsclc medical

"BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65%"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

objective response rate (orr) medical

"non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors shrink by a pre-set amount for a minimum time, counting both complete disappearance and meaningful partial shrinkage. Investors watch ORR because it gives an early, quantitative signal that a treatment is having a direct effect on disease—like the percent of people whose fever drops after taking a medicine—which can influence expectations for later trial success, regulatory approval, and market potential.

progression-free survival (pfs) medical

"showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS)"

Progression-free survival (PFS) measures the length of time in a clinical trial or treatment period during which a patient’s disease does not get worse. Investors watch PFS because longer PFS in trials can signal a drug’s effectiveness, influence regulatory approval and reimbursement decisions, and affect commercial value—think of it as how long a product keeps a problem from returning, which helps estimate future sales and competitive advantage.

pembrolizumab medical

"BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy"

A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.

pi3kα medical

"RAS and PI3Kα programs. The data updates include BBO-8520, a direct inhibitor targeting both"

PI3Kα is a specific form of an enzyme that acts like a cellular switchboard controlling signals for cell growth, survival and movement; think of it as a traffic controller that helps decide when cells divide or stay alive. It matters to investors because drugs that block or modify this enzyme can slow tumor growth or cause side effects, so clinical trial results, approvals or safety concerns around PI3Kα-targeting therapies can significantly affect company value.

hyperglycemia medical

"demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia"

Hyperglycemia is a condition where there is too much sugar in the bloodstream because the body cannot move glucose into cells effectively, like a sink with the drain partially blocked so water pools. It matters to investors because persistent high blood sugar drives demand for diabetes treatments, medical devices and hospital care, affects clinical trial outcomes and regulatory decisions, and can signal long-term cost and liability risks for healthcare companies.

AI-generated analysis. Not financial advice.

• BBO-8520 monotherapy in patients with KRAS^G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRAS^G12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.
• BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy.
• BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation.
• BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; internal combination studies with BBO-8520 and BBO-11818 are anticipated to open this year.
• Company webcast to be held today at 8:30 a.m. Eastern Time (ET).
  

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced positive preliminary safety and antitumor data across its three orally bioavailable, differentiated small molecule RAS and PI3Kα programs. The data updates include BBO-8520, a direct inhibitor targeting both the ON and OFF states of KRAS^G12C; BBO-11818, a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states, and BBO-10203, a RAS-PI3Ka breaker with a novel mechanism of action designed to inhibit the physical interaction between RAS and PI3Kα.

“Today’s data underscore the strength of our differentiated precision oncology portfolio targeting RAS and PI3Kα,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “By focusing on ON biology and leveraging strong chemistry, we are developing highly selective therapies designed to be better tolerated and, as a result, deliver greater anti-tumor activity. We are pleased to see our strategy now being validated clinically. Our differentiated product candidates can be combined both with one another—such as our selective KRAS ON/OFF inhibitors and our potentially first-in-class RAS:PI3Kα breaker—and with standard-of-care therapies, positioning BBOT to enable powerful dual-pathway targeting and improve outcomes for patients with aggressive cancers.”

“BBO-8520 continues to demonstrate a favorable benefit-risk profile, with encouraging efficacy data, a generally tolerable safety profile, and a potentially differentiated liver toxicity profile, both as monotherapy and in combination with pembrolizumab,” said Yong (Ben) Ben, MD, Chief Medical and Development Officer of BBOT. “Similarly, BBO-11818 has also demonstrated favorable tolerability and early signs of efficacy. Notably this data announcement includes the first publicly disclosed monotherapy panKRAS inhibitor response in a patient with pretreated pancreatic ductal adenocarcinoma (PDAC).”

Dr. Ben continued, “Across all BBO-10203 cohorts, the safety profile appears differentiated relative to previously reported data with other PI3Kα kinase inhibitors and demonstrated no hyperglycemia of any grade, even without any restrictions on HbA1c status and glucose level at baseline. We have identified a recommended go-forward dose of 500 mg and have initiated combination cohorts, which represent the primary development opportunity for this asset.”

“Patients with KRAS^G12C mutant NSCLC face a clear unmet need, as durable and well-tolerated treatment options remain limited,” said Ben Solomon, MBBS, FRACP, PhD, medical oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, and an ONKORAS-101 principal investigator. “With immunotherapy widely used, safety and tolerability in combination are critical. The BBO-8520 monotherapy and combination data are compelling, demonstrating meaningful anti-tumor activity with a safety profile well suited for combination therapy. These results highlight BBO-8520’s potential to become an important front-line combination partner with pembrolizumab.”

BBO-8520 (Direct KRAS^G12C ON/OFF)
ONKORAS-101 (NCT06343402) is an open-label, multi-center Phase 1a/1b study designed to evaluate the safety, tolerability, preliminary antitumor activity, and pharmacokinetics of BBO-8520 as a single agent and in combination with pembrolizumab in patients with KRAS^G12C mutant NSCLC. Patients have been enrolled across doses ranging from 100 mg to 700 mg once daily (QD).

BBO-8520 Key Findings

• As of November 15, 2025, a 65% (11/17) objective response rate (ORR) was observed in NSCLC patients with a KRAS^G12C mutation across all dose levels, including 10 partial responses (PRs) and one complete response (CR). Responses appear durable with a 6-month progression-free survival (PFS) of 66% and with 83% of patients remaining on study for ≥6 months.
• In this interim readout, BBO-8520 demonstrated a generally well-tolerated and manageable monotherapy safety profile with a meaningfully differentiated liver toxicity profile.
  • No dose-limiting toxicities (DLTs); no grade ≥4 treatment-related adverse events (TRAEs); no treatment-related serious adverse events (TRSAEs). Nausea, vomiting, and diarrhea were the most common TRAEs.
• BBO-8520 was generally well tolerated in combination with pembrolizumab from 200 mg to 500 mg. A favorable liver safety profile was observed compared to pembrolizumab monotherapy.
• Each efficacy evaluable patient treated with BBO-8520 in combination with pembrolizumab (n=8) experienced a tumor reduction regardless of PD-L1 status, and 3 out of 3 front-line patients and 2 out of 5 patients previously treated with KRAS^G12C inhibitor(s) achieved partial response.
• Encouraging early efficacy signals were seen in patients with KRAS^G12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved PR.
  
  

BBO-8520 Upcoming Catalysts

• BBOT plans to provide additional data updates, including additional pembrolizumab combination efficacy and safety data, in the second half of 2026.
• Combination studies with BBO-10203 are expected to open later in 2026.
  
  

BBO-11818 (Direct panKRAS ON/OFF)
KONQUER-101 (NCT06917079) is evaluating the safety and preliminary antitumor activity of BBO-11818, a panKRAS inhibitor, in heavily pretreated subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Patients have been enrolled across dose levels ranging from 50 mg to 800 mg on a twice daily schedule (BID). Monotherapy dose escalation is ongoing and monotherapy expansions and combination cohorts are planned.

BBO-11818 Key Findings

• As of December 10, 2025, BBO-11818 demonstrated encouraging early anti-tumor activity across dose levels and tumor types, including a PR in a patient with pancreatic ductal adenocarcinoma (PDAC) with a 56% tumor reduction, as well as tumor reductions at higher dose levels. The response was unconfirmed at the time of data cutoff but was subsequently confirmed.
• BBO-11818 monotherapy treatment (n=13) appeared generally tolerable with no DLTs. TRAEs were largely gastrointestinal-related.
• BBO-11818 demonstrated approximately dose-proportional exposure with 600 mg BID covering G12D and G12V mutant alleles.
  
  

BBO-11818 Upcoming Catalysts

• BBOT plans to provide additional data updates, including additional monotherapy and combination efficacy and safety data, in the second half of 2026.
• Combination studies with BBO-10203 are expected to open later in 2026.
  
  

BBO-10203 (RAS:PI3Kα Breaker)
BREAKER-101 (NCT06625775) is a multicenter, open-label, Phase 1a/1b study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BBO-10203 as monotherapy and in combination with trastuzumab, fulvestrant ± ribociclib, or FOLFOX + bevacizumab in patients with locally advanced or metastatic HER2+ breast cancer (BC), HR+/HER2- BC, KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC.

In the monotherapy portion of the study, 24 patients, most of whom were heavily pretreated CRC patients, were enrolled across dose levels from 150 mg to 750 mg QD. Based on safety, PK and target engagement, the 500 mg QD dose has been selected as the recommended dose for expansion, and combination studies with standard-of-care treatments in CRC and BC have been initiated.

BBO-10203 Key Findings

• As of December 10, 2025, the BBO-10203 safety profile has demonstrated the potential to be highly differentiated compared to previously reported data on other PI3Ka-targeting agents. ​
  • No DLTs.
  • No grade ≥3 TRAEs except for one incidence of asymptomatic hypokalemia (lab abnormality)​; no dose reductions​; no TRSAEs.​
  • Without restrictions on baseline enrollment HbA1c status or glucose levels, no hyperglycemia of any grade was observed, consistent with preclinical findings.
• ​BBO-10203 achieved target systemic exposure and rapid full target engagement.
• Clinical benefit was observed in patients with CRC (>80% 3L+) and HR+ BC who were previously heavily treated and tumor reductions were observed in some patients.
  
  

BBO-10203 Upcoming Catalysts

• BBOT plans to provide additional data updates, which will include combination data in HER2+ BC, HR+/HER2- PIK3CA mutant BC and KRAS mutant CRC, in the second half of 2026.
• Combination studies with BBO-8520 and BBO-11818 are expected to open later in 2026.
  
  

Company Webcast
BBOT will host a company webcast on Wednesday, January 7, 2026, at 8:30 am Eastern Time to discuss the data updates for BBO-8520, BBO-11818, and BBO-10203. To participate in the live webcast, participants may register in advance here. A live webcast of the call will be available on the Investors section of BBOT’s website at https://investors.bbotx.com/news-events/events. Following the live webcast, a replay will be available on the company’s website for at least 90 days.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements, which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including express or implied statements relating to the clinical and therapeutic potential of our product candidates, including as monotherapy or in combination with other therapeutics, our plans to continue and expand our clinical trials, our anticipated data readouts, and the timing of these events, are based on the information currently available to us and various assumptions we have made, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; initial and interim data from BBOT’s clinical trials not being indicative of final data; the design and success of ongoing and planned clinical trials; adverse events that may be encountered in BBOT’s clinical trials; risks related to the approval of BBOT’s product candidates and the timing of expected regulatory and business milestones, including the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; the impact of competitive products; risks relating to BBOT’s ability to obtain sufficient supply of materials; and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.

In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

What were BBO-8520 efficacy results for KRASG12C NSCLC reported Jan 7, 2026 by BBOT?

BBO-8520 showed a 65% ORR (11/17) and 66% 6-month PFS as of Nov 15, 2025.

How did BBO-8520 perform in combination with pembrolizumab in BBOT data?

All evaluable combination patients (n=8) had tumor reductions and partial responses across front-line and pretreated cohorts.

What is the confirmed clinical activity of BBO-11818 (BBOT) in pancreatic cancer?

BBO-11818 produced a confirmed partial response with a 56% tumor reduction in a pretreated PDAC patient (data cutoff Dec 10, 2025).

What dose was selected for BBO-10203 expansion and why is it important for BBOT investors?

BBOT selected 500 mg QD as the recommended expansion dose based on safety, PK, and target engagement.

Did BBOT report metabolic safety concerns with BBO-10203 in the Jan 7, 2026 update?

No hyperglycemia of any grade was observed for BBO-10203 despite no baseline HbA1c or glucose restrictions.

When will BBOT provide additional combination and expansion data for these programs?

BBOT expects to provide additional monotherapy and combination data for these programs in the second half of 2026.